Article info

Download PDFPDF

Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Authors

  1. Correspondence to Dr Robert L Coleman, US Oncology Research, Texas Oncology, The Woodlands, TX 77380, USA; rcoledude{at}mac.com
View Full Text

Citation

Coleman RL, Lorusso D, Oaknin A, et al
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

Publication history

  • Received February 16, 2024
  • Accepted April 25, 2024
  • First published June 10, 2024.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.